News
CDC immunization advisory panel endorses Merck's new RSV shot, but not without dissent
The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot Enflonsia, but the decision was hardly resounding from Robert F. | The CDC’s Advisory Committee on Immunization Practices has blessed Merck’s new respiratory syncytial virus shot Enflonsia,
The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...
A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices ...
The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback